1. Home
  2. Analysis
  3. Revlimid
  4. Vitreous-detachment

Revlimid and Vitreous detachment - a phase IV clinical study of FDA data

Summary:

Vitreous detachment is reported as a side effect among people who take Revlimid (lenalidomide), especially for people who are male, 40-49 old, also take Omeprazole, and have Mantle cell lymphoma.

The phase IV clinical study analyzes which people have Vitreous detachment when taking Revlimid. It is created by eHealthMe based on reports of 377,717 people who have side effects when taking Revlimid from the FDA, and is updated regularly.

What is Revlimid?

Revlimid has active ingredients of lenalidomide. It is often used in multiple myeloma. eHealthMe is studying from 378,026 Revlimid users. Check the latest studies of Revlimid.

What is Vitreous detachment?

Vitreous detachment (a condition of the eye in which the vitreous humour separates from the retina) is found to be associated with 411 drugs and 457 conditions by eHealthMe. Check the latest studies of Vitreous detachment.

On Jul, 29, 2026

377,717 people reported to have side effects when taking Revlimid.
Among them, 18 people (0.0%) have Vitreous detachment.

Could Revlimid cause Vitreous detachment?

Among these 18 people:

What is the gender of people who have Vitreous detachment when taking Revlimid? *

  • female: 50 %
  • male: 50 %

What is the age of people who have Vitreous detachment when taking Revlimid? *

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 10 %
  • 40-49: 40 %
  • 50-59: 20 %
  • 60+: 30 %

What are other drugs people take besides Revlimid? *

  1. Omeprazole: 6 people, 33.33%
  2. Zometa: 5 people, 27.78%
  3. Oxycontin: 5 people, 27.78%
  4. Celexa: 5 people, 27.78%
  5. Effexor: 5 people, 27.78%
  6. Flomax: 5 people, 27.78%
  7. Levofloxacin: 5 people, 27.78%
  8. Vicodin: 5 people, 27.78%
  9. Norvasc: 3 people, 16.67%
  10. Amlodipine: 3 people, 16.67%

What are other side effects people have besides Vitreous detachment? *

  1. Type 2 Diabetes: 8 people, 44.44%
  2. Rashes (redness): 7 people, 38.89%
  3. Pain: 7 people, 38.89%
  4. Retinal Degeneration (death of the cells of the retina): 7 people, 38.89%
  5. Pathological Fracture (broken bone caused by disease): 6 people, 33.33%
  6. Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 6 people, 33.33%
  7. Hypokalemia (low potassium): 5 people, 27.78%
  8. Flank Pain (a distressing sensation experienced around the lower back and the upper abdomen): 5 people, 27.78%
  9. Osteonecrosis Of Jaw (death of bone of jaw): 5 people, 27.78%
  10. Osteoarthritis (a joint disease caused by cartilage loss in a joint): 5 people, 27.78%

What are the existing conditions these people have? *

  1. Mantle Cell Lymphoma (cancer of lymphocytes, a type of white blood cell): 2 people, 11.11%
  2. Nausea (feeling of having an urge to vomit): 1 person, 5.56%
  3. Muscle Spasms (muscle contraction): 1 person, 5.56%
  4. Chest Pain: 1 person, 5.56%

* Approximation only. Some reports may have incomplete information.

Do you take Revlimid and have Vitreous detachment?

- Check whether Vitreous detachment is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Revlimid:

Vitreous detachment treatments and more:

How severe was Vitreous detachment and when was it recovered:

Expand to all the drugs that have ingredients of lenalidomide:

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Revlimid:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Vitreous detachment:

Browse all the conditions that are associated with Vitreous detachment:

How the study uses the data?

The study uses data from the FDA. It is based on lenalidomide (the active ingredients of Revlimid) and Revlimid (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.